Contact Us
Synthetic Biology Inspired Medicines
We design and engineer microbial strains rationally to develop innovative bacterial vaccines.
Discover more
Delonix is a world leading biotech company dedicated to developing next generation genetically engineered bacterial vaccines.
Founded by experts in synthetic biology and vaccinology, Delonix aims to transform the development of bacterial vaccines through multiple platforms powered by synthetic biology.
Platforms We Established
BioDVax
platform
BioDesigned bacterial factory for Vaccine. BioDVax engineers polysaccharide, toxin and other components of pathogens, aiming to improve subunit vaccine immunogenicity and optimize manufacturing process with higher yield and more consistent production.
OMV Plus
platform
Proprietary genetically engineered OMV technology platform, which enables robust OMV vaccine candidate generation. Validated by the development of a potential BIC group B meningococcal vaccine.
ProBVax
platform
Programming Bacterial cells for Vaccine. ProBVax leverages rational design and novel bacterial immune checkpoint MOA to develop next generation live-attenuated vaccine, enabling fast optimization of safety and efficacy.
01
Synthetic Biology
Technology
  • Complete toolkits for non-model microbe engineering
  • Data-driven rational design
  • High throughput & automation
02
PathX
Technology
  • PathX: Pathogenic bacteria gene editing
  • Fast, precise and versatile pathogen editing
  • Seemless editing of 16+ pathogens
What's happening about us?
  • Delonix Bioworks Named as "Specialized, Special and New" Small and Mediumsized Enterprises in Shanghai
    Sep 19, 2024
  • Delonix Bioworks and WuXi Vaccines Announce Agreement to Accelerate Development and Manufacturing of Innovative Bacterial Vaccines
    Jan 25, 2024
  • Delonix Bioworks and Zhifei Luzhu Collaborate on the Application of Synthetic Biology Technology in the Vaccine Field
    Jan 02, 2024
  • Delonix Bioworks Wins the First Prize and Intellectual Property Award of the 2023 HKU Innovation&Entrepreneurship Challenge for Early-stage Division
    Dec 26, 2023
  • Delonix Bioworks Closes $14 Million Series Seed Financingto Accelerate the Development of its Innovative Synthetic Vaccines
    Mar 10, 2021